In addition to the promotion of microglial Aβ phagocytosis, DMXBA treatment suppressed the activity of γ-secretase, a proteolytic enzyme that cleaves the membrane-bound APP to generate pathogenic Aβ fragments, both in human neuroblastoma SH-SY5Y cells and the brain of AD model mice [48] (Table 1). The gene discussed is APP; the disease is Alzheimer disease.